Cargando…

Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030

Understanding the level of investment needed for the next decade is vital to achieve the goal of Immunization Agenda 2030 (IA2030). Through the immunization funder perspective, this study estimates both global and regional economic resources required to achieve IA2030 coverage among 194 WHO member c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sriudomporn, Salin, Watts, Elizabeth, Yoon Sim, So, Hutubessy, Raymond, Patenaude, Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850055/
https://www.ncbi.nlm.nih.gov/pubmed/36686400
http://dx.doi.org/10.1016/j.jvacx.2022.100256
_version_ 1784872096331988992
author Sriudomporn, Salin
Watts, Elizabeth
Yoon Sim, So
Hutubessy, Raymond
Patenaude, Bryan
author_facet Sriudomporn, Salin
Watts, Elizabeth
Yoon Sim, So
Hutubessy, Raymond
Patenaude, Bryan
author_sort Sriudomporn, Salin
collection PubMed
description Understanding the level of investment needed for the next decade is vital to achieve the goal of Immunization Agenda 2030 (IA2030). Through the immunization funder perspective, this study estimates both global and regional economic resources required to achieve IA2030 coverage among 194 WHO member countries from 2021 to 2030, against 14 pathogens: Hepatitis B (Hep B), Haemophilus influenzae type b (Hib), Human papillomavirus (HPV), Japanese encephalitis (JE), Measles, Meningitis A (Men A), Streptococcus pneumoniae, Rotavirus, Rubella, Yellow Fever (YF), Diphtheria, Tetanus, Pertussis, and Tuberculosis. The total cost of immunization program, routine vaccine, routine delivery, and non-routine costs (SIA and stockpile) were estimated using WHO coverage forecast for IA2030. Incremental costs of achieving IA2030 for all vaccines and cost per immunized child were also assessed. All costs were calculated for each income and regional level, as well as global level. Scenario analysis and sensitivity analysis were conducted to account for uncertainty in future vaccine pricing and delivery costs. The total cost of immunization programs is $269.8 billion (95% confidence interval: $247.1 - $311.8), of which $152.8 billion is considered as routine vaccine cost, $114.9 billion is routine delivery cost. Non– routine cost for LICs and LMICs totaled $2.1 billion. The incremental cost of achieving coverage goals after 2020 is $89.9 billion ($27.7-$110.1), with upper-middle income countries requiring the largest increase in investment (56.2% of incremental costs). The average immunization cost per child across all countries is $192.6. Scenario analysis using the minimum and maximum vaccines price for fully self-financing countries resulted in total costs ranging from $193.6 and $552.2 billion. The immunization program cost among 194 WHO member countries is expected to increase during this decade. The strategy for resource mobilization and increasing investment from country governments and donors are essential to achieving IA2030 coverage and ensuring sustainable immunization programs.
format Online
Article
Text
id pubmed-9850055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98500552023-01-20 Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030 Sriudomporn, Salin Watts, Elizabeth Yoon Sim, So Hutubessy, Raymond Patenaude, Bryan Vaccine X Regular paper Understanding the level of investment needed for the next decade is vital to achieve the goal of Immunization Agenda 2030 (IA2030). Through the immunization funder perspective, this study estimates both global and regional economic resources required to achieve IA2030 coverage among 194 WHO member countries from 2021 to 2030, against 14 pathogens: Hepatitis B (Hep B), Haemophilus influenzae type b (Hib), Human papillomavirus (HPV), Japanese encephalitis (JE), Measles, Meningitis A (Men A), Streptococcus pneumoniae, Rotavirus, Rubella, Yellow Fever (YF), Diphtheria, Tetanus, Pertussis, and Tuberculosis. The total cost of immunization program, routine vaccine, routine delivery, and non-routine costs (SIA and stockpile) were estimated using WHO coverage forecast for IA2030. Incremental costs of achieving IA2030 for all vaccines and cost per immunized child were also assessed. All costs were calculated for each income and regional level, as well as global level. Scenario analysis and sensitivity analysis were conducted to account for uncertainty in future vaccine pricing and delivery costs. The total cost of immunization programs is $269.8 billion (95% confidence interval: $247.1 - $311.8), of which $152.8 billion is considered as routine vaccine cost, $114.9 billion is routine delivery cost. Non– routine cost for LICs and LMICs totaled $2.1 billion. The incremental cost of achieving coverage goals after 2020 is $89.9 billion ($27.7-$110.1), with upper-middle income countries requiring the largest increase in investment (56.2% of incremental costs). The average immunization cost per child across all countries is $192.6. Scenario analysis using the minimum and maximum vaccines price for fully self-financing countries resulted in total costs ranging from $193.6 and $552.2 billion. The immunization program cost among 194 WHO member countries is expected to increase during this decade. The strategy for resource mobilization and increasing investment from country governments and donors are essential to achieving IA2030 coverage and ensuring sustainable immunization programs. Elsevier 2022-12-28 /pmc/articles/PMC9850055/ /pubmed/36686400 http://dx.doi.org/10.1016/j.jvacx.2022.100256 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/igo/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
spellingShingle Regular paper
Sriudomporn, Salin
Watts, Elizabeth
Yoon Sim, So
Hutubessy, Raymond
Patenaude, Bryan
Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030
title Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030
title_full Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030
title_fullStr Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030
title_full_unstemmed Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030
title_short Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030
title_sort achieving immunization agenda 2030 coverage targets for 14 pathogens: projected product and immunization delivery costs for 194 countries, 2021–2030
topic Regular paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850055/
https://www.ncbi.nlm.nih.gov/pubmed/36686400
http://dx.doi.org/10.1016/j.jvacx.2022.100256
work_keys_str_mv AT sriudompornsalin achievingimmunizationagenda2030coveragetargetsfor14pathogensprojectedproductandimmunizationdeliverycostsfor194countries20212030
AT wattselizabeth achievingimmunizationagenda2030coveragetargetsfor14pathogensprojectedproductandimmunizationdeliverycostsfor194countries20212030
AT yoonsimso achievingimmunizationagenda2030coveragetargetsfor14pathogensprojectedproductandimmunizationdeliverycostsfor194countries20212030
AT hutubessyraymond achievingimmunizationagenda2030coveragetargetsfor14pathogensprojectedproductandimmunizationdeliverycostsfor194countries20212030
AT patenaudebryan achievingimmunizationagenda2030coveragetargetsfor14pathogensprojectedproductandimmunizationdeliverycostsfor194countries20212030